Are ELISA (enzyme-linked immunosorbent assay) and CARD (immunochromatographic lateral-flow) tests the same?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

ELISA and CARD Tests Are NOT the Same

ELISA (enzyme-linked immunosorbent assay) and CARD tests (immunochromatographic lateral flow assays) are fundamentally different diagnostic technologies, though both detect antibodies or antigens through antigen-antibody binding. They differ significantly in methodology, performance characteristics, processing time, and clinical applications.

Key Technical Differences

ELISA Characteristics

  • Laboratory-based platform requiring specialized equipment (microwell readers with specific wavelength filters) 1, 2
  • Processing time: 2-4 hours for conventional ELISA 3
  • Quantitative or semi-quantitative results with precise optical density measurements 2, 4
  • Higher sensitivity: Generally 97-100% in most applications 1, 5
  • Requires trained laboratory personnel and preprocessing of samples in many cases 4
  • Suitable for high-volume batch testing when laboratory resources are available 6

CARD/Lateral Flow Assay Characteristics

  • Point-of-care rapid test requiring no analyzer equipment 1
  • Processing time: 15-20 minutes 1, 2
  • Qualitative or semi-quantitative results (visual interpretation) 1, 2
  • Slightly lower sensitivity: Typically 90-99% depending on the specific assay 1, 7
  • Simple to perform, suitable for self-testing or non-laboratory settings 7
  • Ideal for rapid screening and resource-limited settings 1, 6

Performance Comparison

Recent guideline evidence demonstrates that while both methods show good agreement, they are not interchangeable:

  • For hepatitis D virus testing: Lateral flow assays showed 90.6-99.8% sensitivity and 96.9-100% specificity compared to commercial ELISA assays 1
  • For SARS-CoV-2 antibody detection: Strong correlation exists between lateral flow IgG and ELISA IgG (r = 0.93), but lateral flow detected antibodies in 35-37% of samples while ELISA detected them in 18-31% depending on the target antigen 8
  • Agreement between methods: Cohen's kappa index of 0.80-0.875 indicates substantial but not perfect agreement 9, 7

Clinical Decision Algorithm

When to use ELISA:

  • Laboratory resources and equipment are available
  • High-volume testing is needed
  • Quantitative results are required for monitoring (e.g., treatment response, vaccine efficacy) 10
  • Maximum sensitivity is critical
  • Confirmatory testing after a positive rapid test 1, 6

When to use lateral flow/CARD tests:

  • Point-of-care or field settings
  • Rapid results needed (emergency departments, outbreak investigations)
  • Resource-limited settings without laboratory infrastructure 1, 6
  • Initial screening in high-prevalence populations
  • Self-testing scenarios 7

Critical Caveats

Important limitations to recognize:

  1. Lateral flow tests may miss low-titer infections: The 18 samples testing negative on rapid test but positive on ELISA in hepatitis D studies all had very low viral titres 1

  2. Timing matters: Both methods show reduced sensitivity in early infection (days 1-10: ELISA 58%, lateral flow 55%) 11

  3. Primary vs. secondary infections: For dengue, ELISA detected 85% of primary infections but only 48% of secondary infections, while lateral flow detected 66.7% and 40.7% respectively 12

  4. Negative results don't exclude infection: Particularly in early disease or immunocompromised patients, negative results on either platform require clinical correlation 12

  5. Different antigens yield different results: ELISA targeting spike protein vs. nucleocapsid protein can produce discordant results even within the same platform 8, 10

The choice between ELISA and lateral flow assays should be based on clinical context, available resources, required turnaround time, and whether qualitative screening or quantitative monitoring is needed 1, 2, 6. In settings where both are available, lateral flow can serve as initial screening with ELISA confirmation for positive results.

References

Research

Evaluation of lateral flow and ELISA techniques for detecting IgG and IgM antibodies in COVID-19 cases in Türkiye.

Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit, 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.